Over a decade ago, the FDA recommended HLA-B*15:02 genotyping prior to carbamazepine use, leading to a notable reduction in the occurrence of CBZ-induced SJS/TEN [93]. The gene discussed is HLA-B; the disease is Schwartz-Jampel syndrome.